 Home > Medical News > Medicines Company News > The clinical trial application of Mabwell's innovative drug 9MW3011 injection was accepted by the NMPA

The clinical trial application of Mabwell's innovative drug 9MW3011 injection was accepted by the NMPA

 Last Update: 2022-11-15
 Source: Internet
 Author: User

Tags

variety

ff1 release date

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Mabwell (stock code: 688062.
SH), an innovative biopharmaceutical company with a full industry chain layout, announced that its self-developed 9MW3011 injection for clinical trials of β-thalassemia and polycythemia vera has been accepted
by the National Medical Products Administration (NMPA).

9MW3011 is an innovative target monoclonal antibody independently developed by Mabwell's San Diego Innovation R&D Center in the United States, which is a therapeutic
biologic.
Its target is mainly expressed on the surface of hepatocyte membrane, and 9MW3011 can upregulate the level of heptocyte expression of hepcidin (Hepcidin) through specific binding, inhibit iron absorption and release, and reduce serum iron levels, thereby regulating iron homeostasis
in vivo.

The 9MW3011 indication is intended to include a variety of diseases classified as rare diseases in different parts of the world, such as β-thalassemia, polycythemia vera and other ironostatic related diseases
.
At present, there is no mature and effective treatment or drug in the field of related indications, so 9MW3011 is expected to obtain orphan drug designation in the future and become the first macromolecular drug
in the world to regulate iron homeostasis in vivo.

={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)];

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.